Caerulein (desulfated): frog-derived gut-signaling peptide

What this is

Caerulein (also spelled cerulein, and sold clinically in its sulfated form as ceruletide) is a gut-signaling peptide first isolated from the skin of the Australian green tree frog Hyla caerulea (now Litoria caerulea) in 1967–1968 by Anastasi, Erspamer, and Endean. It belongs to the cholecystokinin (CCK) family — it shares the same active C-terminal sequence as mammalian CCK and binds the same gut receptor (CCKAR, the cholecystokinin A receptor) to trigger gallbladder contraction and stimulate pancreatic enzyme release. This card represents the desulfated form: the native peptide carries a sulfate group on its tyrosine residue, but the sequence stored here (QDYTGWMDF) lacks that modification. The full native caerulein is a decapeptide with an N-terminal pyroglutamate cap and a C-terminal amide (pGlu-Gln-Asp-Tyr(SO₃H)-Thr-Gly-Trp-Met-Asp-Phe-NH₂ as found in Xenopus skin secretions; Coquet and colleagues, 2016, Comparative Biochemistry and Physiology Part D) — the stored nine-residue sequence omits the pyroglutamyl N-cap, the C-terminal amide, and the tyrosine sulfate, all of which are pharmacologically significant.

History

Caerulein was discovered in 1967–1968 during Vittorio Erspamer's systematic survey of bioactive peptides in amphibian skin: the Italian-Australian team led by Anastasi, Erspamer and Endean extracted dried Hyla caerulea skins, traced a hypotensive and gut-contracting principle through countercurrent distribution and ion-exchange chromatography, and resolved a single decapeptide whose C-terminal pentapeptide Gly-Trp-Met-Asp-Phe-NH₂ matched the active site of mammalian gastrin and CCK exactly. Early work by Johnson and colleagues (1970, Gastroenterology) then established that the tyrosine sulfation of caerulein is essential for its potent gastrointestinal actions: desulfated caerulein retains the receptor-binding octapeptide core but loses most of its cholecystokinetic activity at CCKAR. This structure–activity finding made the desulfated form a useful pharmacological tool for distinguishing CCKAR-dependent from CCKAR-independent signaling, and supported its later use as a paired control in receptor-binding studies on rat pancreatic and brain membranes (Saita and colleagues, 1985, Biochemical Pharmacology).

Wechselberger and colleagues (1995, Journal of Molecular Endocrinology) later showed that the Xenopus laevis brain encodes separate precursors for caerulein and for cholecystokinin, demonstrating that amphibians independently maintain both the frog-skin caerulein lineage and a mammalian-type CCK. The evolutionary relationships between frog caerulein gene families and mammalian CCK were systematically analyzed by Roelants and colleagues (2013, PLoS Genetics). Caerulein-like peptides have since been found in the skin secretions of numerous anuran species, including Xenopus ruwenzoriensis (Coquet and colleagues, 2016, Comparative Biochemistry and Physiology Part D), reflecting a deep evolutionary origin.

What it does

Sulfated caerulein (the active native form, marketed as ceruletide) mimics the actions of the gut hormone CCK: it triggers contraction of the gallbladder to release bile acids, stimulates the pancreas to secrete digestive enzymes (lipase, amylase, proteases), slows gastric emptying, and activates the vagal afferent nerve fibers that signal satiety to the brainstem. Clinically, this profile made the sulfated form useful as a cholecystokinetic agent for biliary and pancreatic-function diagnostics, and gave it a documented role in postoperative ileus and biliary colic management (Vincent and colleagues, 1982, Pharmacotherapy).

Desulfated caerulein — the form this card covers — binds CCKAR with dramatically reduced affinity, so these cholecystokinetic actions are greatly attenuated or absent at typical concentrations. Cawston and Miller (2010, British Journal of Pharmacology) reviewed how the CCK1 receptor (CCKAR) mediates this broad spectrum of gastrointestinal and satiety signaling, noting that the sulfate at Tyr is the primary determinant of high-affinity CCKAR engagement. The desulfated peptide retains affinity for the CCKBR (CCK-B / gastrin receptor), which does not require sulfation for ligand binding (Saita and colleagues, 1985, Biochemical Pharmacology) — meaning desulfated caerulein is in practice a research tool for separating CCKAR-driven peripheral effects from CCKBR-driven central effects, rather than an agent of independent clinical interest.

Evidence

Human: No clinical trials of desulfated caerulein. The sulfated parent compound (ceruletide / Takus) was approved historically as a diagnostic cholecystokinetic agent and as an adjunct in pancreatic exocrine function testing, and showed positive controlled-trial results in postoperative ileus and biliary colic (Vincent and colleagues, 1982, Pharmacotherapy). Sincalide (CCK-8, the sulfated octapeptide analog of caerulein's C-terminal core) is FDA-approved as a diagnostic agent to stimulate gallbladder contraction during hepatobiliary scintigraphy and to assess pancreatic exocrine function. IV CCK-8 infusion reduces meal size and accelerates satiety in a dose-dependent fashion in controlled human studies (Rehfeld, 2017, Frontiers in Endocrinology). Removal of the sulfate group abolishes the gallbladder and pancreatic effects that underlie those clinical uses (Johnson and colleagues, 1970, Gastroenterology).

Animal: Sulfated caerulein is the standard pharmacological inducer of experimental acute pancreatitis in rats, mice, and other species — supramaximal intraperitoneal or intravenous doses cause acinar enzyme co-localization, interstitial edema, and inflammation closely mimicking human disease, and it is one of the most widely used pancreatitis models in the field. Desulfated caerulein does not reproduce this pancreatitis phenotype at comparable doses, which is itself diagnostic evidence that the model is mediated through high-affinity CCKAR engagement that the desulfated peptide cannot drive (Saita and colleagues, 1985, Biochemical Pharmacology). In broader CCK physiology, CCKAR-knockout rats (OLETF strain) are hyperphagic and obese, establishing CCKAR's essential role in meal-size regulation, and vagotomy abolishes CCK/caerulein's satiety effect in animals — confirming the vagal afferent pathway is required (Cawston and Miller, 2010, British Journal of Pharmacology).

In vitro: Sulfated caerulein and CCK-8 bind CCKAR with sub-nanomolar affinity via Gq–PLC–IP3–Ca²⁺ signaling in pancreatic acinar cells and gallbladder smooth muscle. Receptor-binding studies on rat pancreatic membranes and brain membranes show that desulfation drops pancreatic-receptor affinity by roughly three orders of magnitude but reduces brain-receptor (CCKBR) affinity by far less (Saita and colleagues, 1985, Biochemical Pharmacology; Cawston and Miller, 2010, British Journal of Pharmacology). Johnson and colleagues (1970, Gastroenterology) demonstrated this differential sulfation-dependence directly for caerulein, with the desulfated form retaining only a small fraction of the parent's gastrointestinal potency. CCKAR agonism drives enzyme exocytosis from acinar cells through calcium oscillations (Cawston and Miller, 2010, British Journal of Pharmacology).

Common questions

What is the difference between caerulein and CCK? Caerulein is a frog skin peptide; CCK is the mammalian gut hormone. They share the same C-terminal active core (Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH₂) and both bind CCKAR, but they are encoded by separate genes and differ at their N-terminal extensions. In the mammalian gut, CCK is the endogenous ligand; caerulein is an exogenous agonist from amphibian skin.

Why does sulfation matter so much? The tyrosine sulfate at position 7 of CCK-8 (the equivalent residue in caerulein) is critical for high-affinity CCKAR binding. Desulfated CCK-8 and desulfated caerulein lose most CCKAR affinity but retain activity at CCKBR (the brain/gastric receptor), which does not require sulfation. This difference underpins the use of desulfated analogs as pharmacological tools for receptor subtype discrimination (Johnson and colleagues, 1970, Gastroenterology; Cawston and Miller, 2010, British Journal of Pharmacology).

What is sincalide? Sincalide (Kinevac) is the synthetic sulfated CCK-8 octapeptide — structurally equivalent to the active form of the caerulein C-terminal fragment. It is the only CCK-related pharmaceutical FDA-approved, used diagnostically to stimulate gallbladder contraction and pancreatic secretion. Sincalide is the sulfated form; this card covers the desulfated variant.

Known effects

• Gallbladder contraction / bile release — Preclinical (sulfated form only; desulfated form attenuated)
• Pancreatic enzyme secretion — Preclinical / diagnostic use (sulfated form; FDA-approved as sincalide)
• Satiety signaling via vagal afferents — Preclinical and human (sulfated CCK-8; minimal for desulfated)
• Slowed gastric emptying — Preclinical (sulfated form)
• CCKBR agonism (anxiogenic at high doses) — Research model (CCK-4 / CCKBR; shared pharmacology)

Safety signals

The sulfated parent compound ceruletide, when given at clinical diagnostic doses, produces nausea, vomiting, abdominal cramping, and occasional hypotension or tachycardia — transient extensions of its CCKAR-agonist pharmacology (Vincent and colleagues, 1982, Pharmacotherapy). At higher (supramaximal) doses in animals, the same compound is deliberately used to induce pancreatitis. Sincalide (sulfated CCK-8, the close clinical analog) shows the same pattern at diagnostic doses: abdominal cramping, nausea, and dizziness are the primary adverse effects, all transient. The desulfated form on this card has no clinical safety database because it has no approved or investigational clinical use; its in-vivo profile in rodents is correspondingly milder than the sulfated parent because the high-affinity CCKAR-driven effects are largely lost (Saita and colleagues, 1985, Biochemical Pharmacology). CCK-4, administered intravenously, reliably induces panic attacks in humans and is used as a controlled panic model — this is a CCKBR-mediated effect and is not relevant at concentrations produced by a normal meal.

Regulatory status

• Sulfated parent (ceruletide / Takus / FI-6934): approved historically as a diagnostic cholecystokinetic agent and pancreatic-function-testing tool (Vincent and colleagues, 1982, Pharmacotherapy). Marketing status varies by country and the molecule is largely of historical clinical importance today.
• Sincalide (Kinevac, sulfated CCK-8): FDA-approved for gallbladder scintigraphy and pancreatic exocrine function testing — the closely related clinical analog still in routine use in the US.
• Desulfated caerulein (this card): research-grade tool compound only. Not approved for any clinical indication and not in active clinical development. No registered trials use desulfated caerulein as a therapeutic.
• WADA: not specifically listed; CCK-family peptides are not on the prohibited list as of the current code.

CCK receptor antagonists (devazepide, loxiglumide, lorglumide) were developed and tested in phase 2 trials for conditions including pancreatitis, IBS, and obesity; none advanced to approval. Phase 1–2 trials of CCK infusion and CCK analogs for obesity identified tachyphylaxis — rapid loss of the satiety response with sustained agonist exposure — as the primary barrier to therapeutic use (Cawston and Miller, 2010, British Journal of Pharmacology; Rehfeld, 2017, Frontiers in Endocrinology).

Related peptides

• Gastrin — a CCKBR agonist produced by G-cells in the gastric antrum; drives gastric acid secretion; shares the active C-terminal tetrapeptide Trp-Met-Asp-Phe-NH₂ with caerulein
• GLP-1 — co-released with CCK postprandially from gut L-cells; overlapping satiety functions; see the GLP-1 family cards for dual-agonist strategies
• Secretin — co-activates pancreatic bicarbonate secretion with CCK; historically confused with CCK (originally called pancreozymin) before their identity was established
• Bombesin / GRP — gastrin-releasing peptide; related satiety-signaling peptide with structural parallels to the CCK/caerulein family (Apponyi and colleagues, 2004)

Mechanism

Desulfated caerulein carries the nine-residue backbone Gln-Asp-Tyr-Thr-Gly-Trp-Met-Asp-Phe. In the active (sulfated) parent, the sulfate group on Tyr is the primary contact for the CCKAR orthosteric binding pocket; its removal reduces receptor affinity by roughly three orders of magnitude (Johnson and colleagues, 1970, Gastroenterology; Saita and colleagues, 1985, Biochemical Pharmacology), shifting the peptide toward partial or negligible CCKAR agonism. Where CCKAR is engaged (at high concentrations or in tissues with amplified coupling), it signals through Gq → PLCβ → IP3 + DAG → intracellular Ca²⁺ rise → PKC activation → enzyme exocytosis in pancreatic acinar cells and smooth-muscle contraction in the gallbladder. Vagal afferent fibers bearing CCKAR at their intestinal terminals are activated by full CCKAR agonism, relaying satiety signals via the vagus nerve to the nucleus tractus solitarius and hypothalamus; this pathway accounts for meal-size reduction. Tachyphylaxis with sustained agonist exposure involves CCKAR downregulation and uncoupling from Gq (Cawston and Miller, 2010, British Journal of Pharmacology). The evolutionary origin of the caerulein gene family in amphibians — independent of mammalian CCK gene lineages — is described by Roelants and colleagues (2013, PLoS Genetics) and Wechselberger and colleagues (1995, Journal of Molecular Endocrinology).

Open questions

• Whether CCKAR-selective agonists with modified pharmacokinetics could overcome tachyphylaxis and produce sustained satiety — the central question blocking CCK-based obesity pharmacotherapy (Cawston and Miller, 2010, British Journal of Pharmacology)
• The relative contributions of peripheral (vagal) versus central CCKAR and CCKBR in mediating satiety and anxiogenic effects of the CCK/caerulein family
• Whether CCK synergizes with GLP-1 receptor agonists (additive satiety via complementary mechanisms) — a potentially exploitable combination for obesity pharmacotherapy
• The structural basis for why the CCKBR does not require tyrosine sulfation for high-affinity binding, unlike CCKAR